Compare ADMA Biologics Inc (ADMA) vs KLA Corp. (KLAC) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ADMA Biologics Inc vs KLA Corp. — how do they compare? ADMA Biologics Inc trades at $9.23 (market cap $2.13B), while KLA Corp. trades at $220.06 (market cap $282.77B). The key difference: KLA Corp. is far larger — about 132.8× ADMA Biologics Inc's market cap, and KLA Corp. pays a 0.43% dividend while ADMA Biologics Inc pays none. Which is the better fit depends on your goals.
| ADMA | KLAC | |
|---|---|---|
Market Cap | $2.13B | $282.77B |
Sector | Health | Technology |
52-Week High | $20.38 | $301.71 |
52-Week Low | $7.60 | $84.39 |
Enterprise Value | $2.20B | $283.96B |
Dividend Yield | — | 0.43% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADMA trades at $9.16, up 2.35% today, with a bullish technical signal from moving averages and oscillators. The company reported strong profitability with a 32.43% net income margin and 43.3% ROE for 2025, though recent EPS results were mixed. Analyst consensus is strongly bullish with an $19.00 price target, but multiple class action lawsuits filed in July 2026 alleging securities fraud create significant near-term uncertainty.
The stock offers substantial upside to analyst targets if legal challenges are resolved favorably, supported by robust fundamentals and projected cash flow growth. Primary risks include the outcome of ongoing litigation and potential reputational damage. Investors should weigh strong financial performance against elevated legal and sentiment risks before establishing a position.
KLA Corporation (KLAC) trades at $216.47, down 8.1% over 24 hours, amid a broader semiconductor selloff. The stock maintains strong fundamentals with a 35.66% net income margin and consistent earnings beats, including Q1 2026 EPS of $0.94 versus $0.917 expected. A 1:10 stock split is scheduled for June 12, 2026, and the company pays a $2.30 dividend. Technical indicators show a bearish short-term trend with support near $209.
KLAC's outlook is supported by robust profitability and AI-driven demand, but high valuation ratios (P/E 66.07) pose risks. Analyst consensus is bullish with a $228.42 price target, though sector volatility and competitive pressures require monitoring. The stock offers growth potential tempered by market sensitivity.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ADMA Biologics Inc
ADMA Biologics is a biopharmaceutical company specializing in plasma-derived therapies for immunodeficient patients. Key products like ASCENIV and BIVIGAM treat primary humoral immunodeficiency and help prevent infectious diseases.
Read more on ADMA →About KLA Corp.
KLA designs and manufactures yield-management and process-monitoring diagnostic and control systems for the semiconductor manufacturing industry. The systems are used to analyze the manufacturing process at various steps in a semiconductor's development. The firm's laser-scanning products are used for wafer qualification, process monitoring, and equipment monitoring. KLA also provides inspection tools and systems for optical metrology and e-beam metrology.
Read more on KLAC →
